A new right-to-try company called Beacon of Hope is stirring some intense discussion. State and federal right-to-try laws could potentially change the fabric of how many investigational studies are conducted. That may happen through firms like Beacon of Hope. However, we don’t know much about the firm. I’m hoping to help change that. Today’s post […]
Richard Garr Q&A on his new Right-To-Try firm Beacon of Hope Read More »
I invited Neuralstem CEO, Richard Garr, to do a Q&A interview and he kindly accepted. The interview provides some novel insights into this major biotech in the stem cell sector. 1. How is Neuralstem doing today? What programs are underway that you find particularly exciting? Garr: Neuralstem is moving on all cylinders these days on
Interview with Neuralstem CEO Richard Garr Read More »
Each year I metaphorically try to look into a crystal ball for stem cell predictions for the coming year and I did so for 2020, but the COVID-19 pandemic threw a monkey wrench into my predictions. It actually kind of blew some up. It also raised some interesting questions and dilemmas. For instance, do many
Grading my 20 stem cell predictions for 2020 Read More »
Every year in December and early January I do a post predicting some key events for the stem cell and regenerative medicine field for the upcoming year and today’s post contains my predictions for 2020. You can see my past 2019 predictions along with my grades for them here. I gave myself a B+ for
20/20 vision? The Niche’s 20 stem cell & regenerative medicine predictions for 2020 Read More »
I’ve been concerned about a stem cell group called MD Stem Cells for many years. Now it comes under more scrutiny from a new must-read piece by Donna Young over at S&P Global. Young’s article reports a puzzling, purported right-to-try (RTT) program that MD Stem Cells appears to working on with Richard Garr. Note that
MD Stem Cells purported Right To Try program Read More »
Every so often I realize I’ve accumulated a bunch of tabs on my browsers of things I need to dive into as time permits, which sometimes translates into a collection of recommended reads here on The Niche. Here are some recommended recent reads in the stem cell/regenerative medicine field and childhood cancer space. It includes
Weekend reads: stem cells, CRISPR, glioma, stroke, RTT & more Read More »
On Thursday here at UC Davis School of Medicine we held our second annual Stem Cell Ethics Symposium. The symposium was organized by Drs. Mark Yarborough and Nanette Joyce as well as me. In this post I report on key take homes from the meeting and summarize the specific talks. As far as I know, this is one of the few
Meeting review of unique stem cell ethics symposium at UC Davis School of Medicine Read More »
We here at UC Davis School of Medicine are gearing up for our 2nd annual Stem Cell Ethics Symposium (see flyer). As one of the organizers, I’m really excited about our lineup of speakers including Timothy Caulfield, Leigh Turner, Alison Sorkin, Mary Ann Chirba, and Richard Garr as well as others. We will be focusing
UC Davis 2nd Annual Stem Cell Ethics Symposium: Save the Date Feb. 12 Read More »
With one week left to vote to pick the top 12 finalists for the Stem Cell Person of the Year 2014 Award, we have more than 2,800 votes in so far. From the top 12 vote-getters, I will choose the winner. This is the third year of this award. I self-fund this award out of
Stem Cell Person of the Year Award 2014 Voting: Who Will Be Finalists? Read More »
Nominations have closed and we have more than two dozen nominations for Stem Cell Person of the Year 2014. It’s an exciting, diverse group including some news faces as well as nominees from years past as well. Happy Stem Cell Day! You can now vote for your choice for the top finalists in the poll
Stem Cell Person of the Year 2014 Award: Vote To Choose 12 Finalists Read More »